Malignancy after heart transplantation.

نویسندگان

  • Po-Lin Chen
  • Hsiao-Huang Chang
  • I-Ming Chen
  • Shiau-Ting Lai
  • Chun-Che Shih
  • Zen-Chung Weng
  • Yuan-Chen Hsieh
  • An-Hang Yang
چکیده

BACKGROUND The purpose of this study was to assess the incidence and type of malignancies after heart transplantation at a medical institute in Taiwan. METHODS From January 1987 to December 2008, a total of 66 patients who survived more than 30 days after transplantation were enrolled in this study. RESULTS Of the 66 heart transplant recipients, 8 (12.1%) post-transplant malignancies were diagnosed: 5 posttransplant lymphoproliferative diseases (PTLD), 1 prostate cancer, 1 lung cancer, and 1 squamous cell carcinoma of the cheek. The clinical presentations were diverse, and the diagnoses were confirmed by biopsy. Only 1 patient died of PTLD and subsequent multiple organ failure. CONCLUSION Cancer is a limiting factor for long-term survival after heart transplantation. The most common type in this study was PTLD. Early detection and aggressive treatment results in good response and preserves the allograft.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

NINE CASES OF MALIGNANCY AFTER KIDNEY TRANSPLANTATION

Renal transplantation is considered one of the best long-term therapies for chronic renal failure, but unfortunately the incidence of malignancy significantly increases in renal transplant recipients. We analyzed nine cases of malignancy in 200 renal transplant recipients occurring in a 12-year follow-up in Imam hospital of Tehran University, Tehran, Iran. According to this study, the organ...

متن کامل

Transferral of malignancy as a complication of organ transplantation: an insuperable problem?

A case of inadvertent transplantation of malignancy is presented in detail. The donor was a 36-year-old woman with an unsuspected disseminated carcinoma of lung, and the renal and tumour transplant recipient a 53-year-old man. The transplanted tumour remained clinically "silent" and was discovered only a necropsy after the recipient's death from ischaemic heart disease. The phenomena of de novo...

متن کامل

Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update

Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancers. In kidney transplantation, evidence from registry studies indicates a lower rate of de novo ma...

متن کامل

De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study

Organ transplant recipients appear to have a higher risk of de novo malignancy. The aim of the study was designed to estimate cancer risk in heart, lung, kidney and liver transplant recipients. The cohort study used the Taiwan National Health Insurance Research Database (1996-2011) and followed the outcomes of organ recipients until 2012. De novo cancer and mortality rates after organ transplan...

متن کامل

Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy

OBJECTIVE The aim of this study was to analyze the distribution of malignancies in patients after heart transplantation (HTX) and to evaluate the risk factors including immunosuppressive therapy with regard to the development of malignancies and survival. Special emphasis was placed on the effects of a mammalian target of rapamycin (mTOR) containing immunosuppressive regimen. METHODS A total ...

متن کامل

Statins and the Risk of Cancer after Heart Transplantation

Background—Although newer immunosuppressive agents, such as mTOR (mammalian target of rapamycin) inhibitors, have lowered the occurrence of malignancies after transplantation, cancer is still a leading cause of death late after heart transplantation. Statins may have an impact on clinical outcomes beyond their lipid-lowering effects. The aim of the present study was to delineate whether statin ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Journal of the Chinese Medical Association : JCMA

دوره 72 11  شماره 

صفحات  -

تاریخ انتشار 2009